Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure

BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the pat...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Konstantinos Iliodromitis [verfasserIn] Zsuzsanna Balogh [verfasserIn] Filippos Triposkiadis [verfasserIn] Spyridon Deftereos [verfasserIn] Dimitrios Vrachatis [verfasserIn] Nana-Yaw Bimpong-Buta [verfasserIn] Fabian Schiedat [verfasserIn] Harilaos Bogossian [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	wearable cardioverter defibrillator life vest physical activity ejection fraction heart failure sudden cardiac death

Übergeordnetes Werk:	In: Frontiers in Cardiovascular Medicine - Frontiers Media S.A., 2015, 10(2023)
Übergeordnetes Werk:	volume:10 ; year:2023

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3389/fcvm.2023.1176710

Katalog-ID:	DOAJ090408152

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ090408152
003	DE-627
005	20230526111024.0
007	cr uuu---uuuuu
008	230526s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3389/fcvm.2023.1176710 \|2 doi
035			\|a (DE-627)DOAJ090408152
035			\|a (DE-599)DOAJ8c29382dc11345eeb76aec020f26fb5f
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC666-701
100	0		\|a Konstantinos Iliodromitis \|e verfasserin \|4 aut
245	1	0	\|a Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment.
650		4	\|a wearable cardioverter defibrillator
650		4	\|a life vest
650		4	\|a physical activity
650		4	\|a ejection fraction
650		4	\|a heart failure
650		4	\|a sudden cardiac death
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a Konstantinos Iliodromitis \|e verfasserin \|4 aut
700	0		\|a Zsuzsanna Balogh \|e verfasserin \|4 aut
700	0		\|a Filippos Triposkiadis \|e verfasserin \|4 aut
700	0		\|a Spyridon Deftereos \|e verfasserin \|4 aut
700	0		\|a Dimitrios Vrachatis \|e verfasserin \|4 aut
700	0		\|a Nana-Yaw Bimpong-Buta \|e verfasserin \|4 aut
700	0		\|a Nana-Yaw Bimpong-Buta \|e verfasserin \|4 aut
700	0		\|a Fabian Schiedat \|e verfasserin \|4 aut
700	0		\|a Harilaos Bogossian \|e verfasserin \|4 aut
700	0		\|a Harilaos Bogossian \|e verfasserin \|4 aut
773	0	8	\|i In \|t Frontiers in Cardiovascular Medicine \|d Frontiers Media S.A., 2015 \|g 10(2023) \|w (DE-627)793951607 \|w (DE-600)2781496-8 \|x 2297055X \|7 nnns
773	1	8	\|g volume:10 \|g year:2023
856	4	0	\|u https://doi.org/10.3389/fcvm.2023.1176710 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/8c29382dc11345eeb76aec020f26fb5f \|z kostenfrei
856	4	0	\|u https://www.frontiersin.org/articles/10.3389/fcvm.2023.1176710/full \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2297-055X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 10 \|j 2023

Indexfelder

author_variant	k i ki k i ki z b zb f t ft s d sd d v dv n y b b nybb n y b b nybb f s fs h b hb h b hb
matchkey_str	article:2297055X:2023----::sesnpyiaatvtwtteerbeadoetreirlaoiptetwt
hierarchy_sort_str	2023
callnumber-subject-code	RC
publishDate	2023
allfields	10.3389/fcvm.2023.1176710 doi (DE-627)DOAJ090408152 (DE-599)DOAJ8c29382dc11345eeb76aec020f26fb5f DE-627 ger DE-627 rakwb eng RC666-701 Konstantinos Iliodromitis verfasserin aut Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment. wearable cardioverter defibrillator life vest physical activity ejection fraction heart failure sudden cardiac death Diseases of the circulatory (Cardiovascular) system Konstantinos Iliodromitis verfasserin aut Zsuzsanna Balogh verfasserin aut Filippos Triposkiadis verfasserin aut Spyridon Deftereos verfasserin aut Dimitrios Vrachatis verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Fabian Schiedat verfasserin aut Harilaos Bogossian verfasserin aut Harilaos Bogossian verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 10(2023) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:10 year:2023 https://doi.org/10.3389/fcvm.2023.1176710 kostenfrei https://doaj.org/article/8c29382dc11345eeb76aec020f26fb5f kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2023.1176710/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2023
spelling	10.3389/fcvm.2023.1176710 doi (DE-627)DOAJ090408152 (DE-599)DOAJ8c29382dc11345eeb76aec020f26fb5f DE-627 ger DE-627 rakwb eng RC666-701 Konstantinos Iliodromitis verfasserin aut Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment. wearable cardioverter defibrillator life vest physical activity ejection fraction heart failure sudden cardiac death Diseases of the circulatory (Cardiovascular) system Konstantinos Iliodromitis verfasserin aut Zsuzsanna Balogh verfasserin aut Filippos Triposkiadis verfasserin aut Spyridon Deftereos verfasserin aut Dimitrios Vrachatis verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Fabian Schiedat verfasserin aut Harilaos Bogossian verfasserin aut Harilaos Bogossian verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 10(2023) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:10 year:2023 https://doi.org/10.3389/fcvm.2023.1176710 kostenfrei https://doaj.org/article/8c29382dc11345eeb76aec020f26fb5f kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2023.1176710/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2023
allfields_unstemmed	10.3389/fcvm.2023.1176710 doi (DE-627)DOAJ090408152 (DE-599)DOAJ8c29382dc11345eeb76aec020f26fb5f DE-627 ger DE-627 rakwb eng RC666-701 Konstantinos Iliodromitis verfasserin aut Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment. wearable cardioverter defibrillator life vest physical activity ejection fraction heart failure sudden cardiac death Diseases of the circulatory (Cardiovascular) system Konstantinos Iliodromitis verfasserin aut Zsuzsanna Balogh verfasserin aut Filippos Triposkiadis verfasserin aut Spyridon Deftereos verfasserin aut Dimitrios Vrachatis verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Fabian Schiedat verfasserin aut Harilaos Bogossian verfasserin aut Harilaos Bogossian verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 10(2023) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:10 year:2023 https://doi.org/10.3389/fcvm.2023.1176710 kostenfrei https://doaj.org/article/8c29382dc11345eeb76aec020f26fb5f kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2023.1176710/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2023
allfieldsGer	10.3389/fcvm.2023.1176710 doi (DE-627)DOAJ090408152 (DE-599)DOAJ8c29382dc11345eeb76aec020f26fb5f DE-627 ger DE-627 rakwb eng RC666-701 Konstantinos Iliodromitis verfasserin aut Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment. wearable cardioverter defibrillator life vest physical activity ejection fraction heart failure sudden cardiac death Diseases of the circulatory (Cardiovascular) system Konstantinos Iliodromitis verfasserin aut Zsuzsanna Balogh verfasserin aut Filippos Triposkiadis verfasserin aut Spyridon Deftereos verfasserin aut Dimitrios Vrachatis verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Fabian Schiedat verfasserin aut Harilaos Bogossian verfasserin aut Harilaos Bogossian verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 10(2023) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:10 year:2023 https://doi.org/10.3389/fcvm.2023.1176710 kostenfrei https://doaj.org/article/8c29382dc11345eeb76aec020f26fb5f kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2023.1176710/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2023
allfieldsSound	10.3389/fcvm.2023.1176710 doi (DE-627)DOAJ090408152 (DE-599)DOAJ8c29382dc11345eeb76aec020f26fb5f DE-627 ger DE-627 rakwb eng RC666-701 Konstantinos Iliodromitis verfasserin aut Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment. wearable cardioverter defibrillator life vest physical activity ejection fraction heart failure sudden cardiac death Diseases of the circulatory (Cardiovascular) system Konstantinos Iliodromitis verfasserin aut Zsuzsanna Balogh verfasserin aut Filippos Triposkiadis verfasserin aut Spyridon Deftereos verfasserin aut Dimitrios Vrachatis verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Nana-Yaw Bimpong-Buta verfasserin aut Fabian Schiedat verfasserin aut Harilaos Bogossian verfasserin aut Harilaos Bogossian verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 10(2023) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:10 year:2023 https://doi.org/10.3389/fcvm.2023.1176710 kostenfrei https://doaj.org/article/8c29382dc11345eeb76aec020f26fb5f kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2023.1176710/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2023
language	English
source	In Frontiers in Cardiovascular Medicine 10(2023) volume:10 year:2023
sourceStr	In Frontiers in Cardiovascular Medicine 10(2023) volume:10 year:2023
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	wearable cardioverter defibrillator life vest physical activity ejection fraction heart failure sudden cardiac death Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Frontiers in Cardiovascular Medicine
authorswithroles_txt_mv	Konstantinos Iliodromitis @@aut@@ Zsuzsanna Balogh @@aut@@ Filippos Triposkiadis @@aut@@ Spyridon Deftereos @@aut@@ Dimitrios Vrachatis @@aut@@ Nana-Yaw Bimpong-Buta @@aut@@ Fabian Schiedat @@aut@@ Harilaos Bogossian @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	793951607
id	DOAJ090408152
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ090408152</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230526111024.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230526s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fcvm.2023.1176710</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ090408152</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8c29382dc11345eeb76aec020f26fb5f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Konstantinos Iliodromitis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: &lt; 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p &lt; 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">wearable cardioverter defibrillator</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">life vest</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">physical activity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ejection fraction</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sudden cardiac death</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Konstantinos Iliodromitis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zsuzsanna Balogh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Filippos Triposkiadis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Spyridon Deftereos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dimitrios Vrachatis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nana-Yaw Bimpong-Buta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nana-Yaw Bimpong-Buta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabian Schiedat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harilaos Bogossian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harilaos Bogossian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Cardiovascular Medicine</subfield><subfield code="d">Frontiers Media S.A., 2015</subfield><subfield code="g">10(2023)</subfield><subfield code="w">(DE-627)793951607</subfield><subfield code="w">(DE-600)2781496-8</subfield><subfield code="x">2297055X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2023</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fcvm.2023.1176710</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8c29382dc11345eeb76aec020f26fb5f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/articles/10.3389/fcvm.2023.1176710/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2297-055X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2023</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Konstantinos Iliodromitis
spellingShingle	Konstantinos Iliodromitis misc RC666-701 misc wearable cardioverter defibrillator misc life vest misc physical activity misc ejection fraction misc heart failure misc sudden cardiac death misc Diseases of the circulatory (Cardiovascular) system Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
authorStr	Konstantinos Iliodromitis
ppnlink_with_tag_str_mv	@@773@@(DE-627)793951607
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	2297055X
topic_title	RC666-701 Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure wearable cardioverter defibrillator life vest physical activity ejection fraction heart failure sudden cardiac death
topic	misc RC666-701 misc wearable cardioverter defibrillator misc life vest misc physical activity misc ejection fraction misc heart failure misc sudden cardiac death misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc wearable cardioverter defibrillator misc life vest misc physical activity misc ejection fraction misc heart failure misc sudden cardiac death misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc wearable cardioverter defibrillator misc life vest misc physical activity misc ejection fraction misc heart failure misc sudden cardiac death misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Frontiers in Cardiovascular Medicine
hierarchy_parent_id	793951607
hierarchy_top_title	Frontiers in Cardiovascular Medicine
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)793951607 (DE-600)2781496-8
title	Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
ctrlnum	(DE-627)DOAJ090408152 (DE-599)DOAJ8c29382dc11345eeb76aec020f26fb5f
title_full	Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
author_sort	Konstantinos Iliodromitis
journal	Frontiers in Cardiovascular Medicine
journalStr	Frontiers in Cardiovascular Medicine
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
author_browse	Konstantinos Iliodromitis Zsuzsanna Balogh Filippos Triposkiadis Spyridon Deftereos Dimitrios Vrachatis Nana-Yaw Bimpong-Buta Fabian Schiedat Harilaos Bogossian
container_volume	10
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	Konstantinos Iliodromitis
doi_str_mv	10.3389/fcvm.2023.1176710
author2-role	verfasserin
title_sort	assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
callnumber	RC666-701
title_auth	Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
abstract	BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment.
abstractGer	BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment.
abstract_unstemmed	BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: < 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p < 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
url	https://doi.org/10.3389/fcvm.2023.1176710 https://doaj.org/article/8c29382dc11345eeb76aec020f26fb5f https://www.frontiersin.org/articles/10.3389/fcvm.2023.1176710/full https://doaj.org/toc/2297-055X
remote_bool	true
author2	Konstantinos Iliodromitis Zsuzsanna Balogh Filippos Triposkiadis Spyridon Deftereos Dimitrios Vrachatis Nana-Yaw Bimpong-Buta Fabian Schiedat Harilaos Bogossian
author2Str	Konstantinos Iliodromitis Zsuzsanna Balogh Filippos Triposkiadis Spyridon Deftereos Dimitrios Vrachatis Nana-Yaw Bimpong-Buta Fabian Schiedat Harilaos Bogossian
ppnlink	793951607
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3389/fcvm.2023.1176710
callnumber-a	RC666-701
up_date	2024-07-03T14:35:53.132Z
_version_	1803568916080885760
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ090408152</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230526111024.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230526s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fcvm.2023.1176710</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ090408152</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8c29382dc11345eeb76aec020f26fb5f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Konstantinos Iliodromitis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">BackgroundThe wearable cardioverter defibrillator (WCD), (LifeVest, ZOLL, Pittsburgh, PA, USA) is a medical device designed for the temporary detection and treatment of malignant ventricular tachyarrhythmias. WCD telemonitoring features enable the evaluation of the physical activity (PhA) of the patients. We sought to assess with the WCD the PhA of patients with newly diagnosed heart failure.MethodsWe collected and analyzed the data of all patients treated with the WCD in our clinic. Patients with newly diagnosed ischemic, or non-ischemic cardiomyopathy and severely reduced ejection fraction, who were treated with the WCD for at least 28 consecutive days and had a compliance of at least 18 h the day were included.ResultsSeventy-seven patients were eligible for analysis. Thirty-seven patients suffered from ischemic and 40 from non-ischemic heart disease. The average days the WCD was carried was 77.3 ± 44.6 days and the mean wearing time was 22.8 ± 2.1 h. The patients showed significantly increased PhA measured by daily steps between the first two and the last two weeks (Mean steps in the first 2 weeks: 4,952.6 ± 3,052.7 vs. mean steps in the last 2 weeks: 6,119.6 ± 3,776.2, p-value: &lt; 0.001). In the end of the surveillance period an increase of the ejection fraction was observed (LVEF-before: 25.8 ± 6.6% vs. LVEF-after: 37.5 ± 10.6%, p &lt; 0.001). Improvement of the EF did not correlate with the improvement of PhA.ConclusionThe WCD provides useful information regarding patient PhA and may be additionally utilized for early heart failure treatment adjustment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">wearable cardioverter defibrillator</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">life vest</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">physical activity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ejection fraction</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sudden cardiac death</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Konstantinos Iliodromitis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zsuzsanna Balogh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Filippos Triposkiadis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Spyridon Deftereos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dimitrios Vrachatis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nana-Yaw Bimpong-Buta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nana-Yaw Bimpong-Buta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabian Schiedat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harilaos Bogossian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harilaos Bogossian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Cardiovascular Medicine</subfield><subfield code="d">Frontiers Media S.A., 2015</subfield><subfield code="g">10(2023)</subfield><subfield code="w">(DE-627)793951607</subfield><subfield code="w">(DE-600)2781496-8</subfield><subfield code="x">2297055X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2023</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fcvm.2023.1176710</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8c29382dc11345eeb76aec020f26fb5f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/articles/10.3389/fcvm.2023.1176710/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2297-055X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2023</subfield></datafield></record></collection>
score	7.401106

Nicht das Richtige dabei?

Schreiben Sie uns!

Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?